Enanta Pharmaceuticals | ENTA - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.63B 54M 2026-06
Amgen USD 1.72B 134M 2026-06
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Biogen USD 709.7M 155.4M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Halozyme Therapeutics USD 57M 10.71M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Immunic USD 3.45M 451K 2025-12
Incyte USD 351.73M 23.64M 2026-06
Insmed USD 247.47M 208K 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
J&J USD 6.42B 381M 2026-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Ligand Pharmaceuticals USD 29.12M 8.29M 2026-06
Merck USD 2.89B 219M 2026-06
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 3.41B 496M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Roche Holding CHF 6.37B 908M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06